Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis

Biochemical and Biophysical Research Communications

Volumn 437, Issue 1, 2013, Pages 1-6

  Wang, Bing ^a   Wang, Xin bao ^a   Chen, Li yu ^a   Huang, Ling ^a   Dong, Rui zen ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

AMPK; Apoptosis; Belinostat; Pancreatic cancer; TAK1

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACETYLCYSTEINE; BELINOSTAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL SELECTION; CELL SURVIVAL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

(MTOR); ACC; ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASE; AMPK; APOPTOSIS; BELINOSTAT; H(2)O(2); HDACI; HISTONE DEACETYLASES INHIBITOR; HYDROGEN PEROXIDE; MAMMALIAN TARGET OF RAPAMYCIN; N-ACETYL-CYSTEINE; NAC; PANCREATIC CANCER; REACTIVE OXYGEN SPECIES; ROS; TAK1; TRANSFORMING GROWTH FACTOR-Β-ACTIVATING KINASE 1;

AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; HUMANS; HYDROXAMIC ACIDS; MAP KINASE KINASE KINASES; PANCREATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84880511425     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.05.090     Document Type: Article

References (40)

1. Jenks S. AACR highlights: promise for treating pancreatic cancer. J. Natl. Cancer Inst. 2011, 103:786-787.
2. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
3. Colucci G., Labianca R., Di Costanzo F., Gebbia V., Carteni G., Massidda B., Dapretto E., Manzione L., Piazza E., Sannicolo M., Ciaparrone M., Cavanna L., Giuliani F., Maiello E., Testa A., Pederzoli P., Falconi M., Gallo C., Di Maio M., Perrone F. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J. Clin. Oncol. 2010, 28:1645-1651.
4. Costello E., Neoptolemos J.P. Pancreatic cancer in 2010: new insights for early intervention and detection. Nat. Rev. Gastroenterol. Hepatol. 2010, 8(2011):71-73.
5. Oikawa T., Hitomi J., Kono A., Kaneko E., Yamaguchi K. Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. Int. J. Pancreatol. 1995, 18:15-23.
6. Wong H.H., Lemoine N.R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:412-422.
7. Janku F., Lee J.J., Tsimberidou A.M., Hong D.S., Naing A., Falchook G.S., Fu S., Luthra R., Garrido-Laguna I., Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 2011, 6:e22769.
8. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 2009, 15:3958-3969.
9. Dovzhanskiy D.I., Arnold S.M., Hackert T., Oehme I., Witt O., Felix K., Giese N., Werner J. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer 2012, 12:226.
10. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
11. Koutsounas I., Giaginis C., Patsouris E., Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J. Gastroenterol. 2013, 19:813-828.
12. Chien W., Lee D.H., Zheng Y., Wuensche P., Alvarez R., Wen D.L., Aribi A.M., Thean S.M., Doan N.B., Said J.W., Koeffler H.P. Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol. Carcinog. 2013, [Epub ahead of print].
13. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
14. Chen M.B., Shen W.X., Yang Y., Wu X.Y., Gu J.H., Lu P.H. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J. Cell. Physiol. 2011, 226:1915-1925.
15. Chen M.B., Wu X.Y., Gu J.H., Guo Q.T., Shen W.X., Lu P.H. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem. Biophys. 2010, 60:311-322.
16. Rocha G.Z., Dias M.M., Ropelle E.R., Osorio-Costa F., Rossato F.A., Vercesi A.E., Saad M.J., Carvalheira J.B. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin. Cancer Res. 2011, 17:3993-4005.
17. Sun H., Yu T., Li J. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett. 2011, 310:118-128.
18. Zhang W.B., Wang Z., Shu F., Jin Y.H., Liu H.Y., Wang Q.J., Yang Y. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem. 2010, 285:40461-40471.
19. Chen M.B., Wu X.Y., Gu J.H., Guo Q.T., Shen W.X., Lu P.H. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem. Biophys. 2011, 60:311-322.
20. Ji C., Yang B., Yang Y.L., He S.H., Miao D.S., He L., Bi Z.G. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 2010, 29:6557-6568.
21. Kimura N., Tokunaga C., Dalal S., Richardson C., Yoshino K., Hara K., Kemp B.E., Witters L.A., Mimura O., Yonezawa K. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 2003, 8:65-79.
22. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
23. Meisse D., Van de Casteele M., Beauloye C., Hainault I., Kefas B.A., Rider M.H., Foufelle F., Hue L. Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett. 2002, 526:38-42.
24. Wu C.-H., Cao C., Kim J.H., Hsu C.-H., Wanebo H.J., Bowen W.D., Xu J., Marshall J. Trojan-horse nanotube on-command intracellular drug delivery. Nano Lett. 2012, 12:5475-5480.
25. Peterson-Roth E., Reynolds M., Quievryn G., Zhitkovich A. Mismatch repair proteins are activators of toxic responses to chromium-DNA damage. Mol. Cell. Biol. 2005, 25:3596-3607.
26. Zheng Q.Y., Jin F.S., Yao C., Zhang T., Zhang G.H., Ai X. Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem. Biophys. Res. Commun. 2012, 419:714-747.
27. Ju T.C., Chen H.M., Lin J.T., Chang C.P., Chang W.C., Kang J.J., Sun C.P., Tao M.H., Tu P.H., Chang C., Dickson D.W., Chern Y. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J. Cell Biol. 2011, 194:209-227.
28. Stein S.C., Woods A., Jones N.A., Davison M.D., Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 2000, 345(Pt 3):437-443.
29. Cao C., Rioult-Pedotti M., Paolo M., Yu C., Tiwari R., Parang K., Spaller M.R., Goebel D.J., Marshall J. Impairment of TrkB-PSD-95 signaling in angelman syndrome. Plos Biol. 2013, 11:e1001478.
30. Park S.H., Gammon S.R., Knippers J.D., Paulsen S.R., Rubink D.S., Winder W.W. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J. Appl. Physiol. 2002, 92:2475-2482.
31. Sakoda H., Ogihara T., Anai M., Fujishiro M., Ono H., Onishi Y., Katagiri H., Abe M., Fukushima Y., Shojima N., Inukai K., Kikuchi M., Oka Y., Asano T. Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E1239-E1244.
32. Sanders M.J., Ali Z.S., Hegarty B.D., Heath R., Snowden M.A., Carling D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 2007, 282:32539-32548.
33. Liangpunsakul S., Wou S.E., Zeng Y., Ross R.A., Jayaram H.N., Crabb D.W. Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295:G1173-G1181.
34. Chen Z., Shen X., Shen F., Zhong W., Wu H., Liu S., Lai J. TAK1 activates AMPK-dependent cell death pathway in hydrogen peroxide-treated cardiomyocytes, inhibited by heat shock protein-70. Mol. Cell. Biochem. 2013, 377:35-44.
35. Herrero-Martin G., Hoyer-Hansen M., Garcia-Garcia C., Fumarola C., Farkas T., Lopez-Rivas A., Jaattela M. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 2009, 28:677-685.
36. 2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005, 2:21-33.
37. Abbott M.J., Edelman A.M., Turcotte L.P. CaMKK is an upstream signal of AMP-activated protein kinase in regulation of substrate metabolism in contracting skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 297:R1724-R1732.
38. Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K., Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B., Kastan M.B., Walker C.L. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl. Acad. Sci. USA 2010, 107:4153-4158.
39. Chen L., Xu B., Liu L., Luo Y., Yin J., Zhou H., Chen W., Shen T., Han X., Huang S. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab. Invest. 2010, 90:762-773.
40. Cao C., Lu S., Kivlin R., Wallin B., Card E., Bagdasarian A., Tamakloe T., Chu W.M., Guan K.L., Wan Y. AMP-activated protein kinase contributes to UV- and H2O2-induced apoptosis in human skin keratinocytes. J. Biol. Chem. 2008, 283:28897-28908.